Jack W. Lasersohn
General Partner @ The Vertical Group
East Hampton, United States
Jack W. Lasersohn is a Series C investor at The Vertical Group in East Hampton focused on Health Care and Biotechnology. Jack Lasersohn has thirty years of experience in health care venture capital investments. Prior to joining The Vertical Group's predecessor, F. Eberstadt in 1981 as a member of its venture capital division, Jack Lasersohn was a corporate attorney with Cravath, Swaine & Moore. Jack Lasersohn has served on the boards of over thirty medicalcompanies and currently serves on the Boards of Directors of Anova, Masimo Corporation, Oncomed, Photothera and Silk Road Medical. He previously served on the boards of Bacchus Vascular, CardioThoracic Systems, Inc., Cardiovascular Imaging Systems, Inc., E.P. Technologies, Integrated Vascular Systems, Kyphon Inc, Metabolix, Proteolix and TetraLogic Pharmaceuticals . Jack Lasersohn served on the Executive Committee of the Board of Directors of the National Venture Capital Association and is a past Chairman of the Medical Industry Group of the NVCA . He was the recipient of the NVCA’s Outstanding Service Award in 2008. In 2011, Jack Lasersohn was appointed by the Office of the President to serve as an Entrepeneur in Residence at the FDA to develop an Innovation Pathway for medical devices. In 2012 he was appointed by the Secretary of HHS as a guest panel member of the Medicare Coverage and Advisory Committee (MEDCAC). He received a B.S. degree in Physics from Tufts University, an M.A. from The Fletcher School of Law and Diplomacy, and a J.D. from Yale Law School.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Jack W. Lasersohn invests in
Stages Jack W. Lasersohn invests in
Countries Jack W. Lasersohn invests in
Investment Focus
Industry
- Health Care 4 (33%)
- Biotechnology 3 (25%)
- Medical Device 3 (25%)
- Medical 2 (17%)
- Pharmaceutical 2 (17%)
Stage
- Series C 3 (25%)
- Series B 2 (17%)
- Seed 1 (8%)
- Series A 1 (8%)
- Series D 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Silk Road Medical
|
Silk Road Medical believes that by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with arterial disease. Our history is one of deep collaboration with vascular surgeons and our future will be guided by continuous learning, observation, and improvement.Silk Road advances patient care. Silk Road Medical Inc. was founded in 2007 and is based in Sunnyvale, California. | $47M / Series C / Jul 18, 2017 | |
|
Silk Road Medical
|
Silk Road Medical believes that by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with arterial disease. Our history is one of deep collaboration with vascular surgeons and our future will be guided by continuous learning, observation, and improvement.Silk Road advances patient care. Silk Road Medical Inc. was founded in 2007 and is based in Sunnyvale, California. | $57M / Private Equity / Oct 20, 2015 | |
InSpeed Networks
|
InSpeed’s service enables high-quality voice calls, smooth video conferencing and responsive applications over any Internet connection. | $2M / Seed / Aug 14, 2015 | |
|
Silk Road Medical
|
Silk Road Medical believes that by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with arterial disease. Our history is one of deep collaboration with vascular surgeons and our future will be guided by continuous learning, observation, and improvement.Silk Road advances patient care. Silk Road Medical Inc. was founded in 2007 and is based in Sunnyvale, California. | $13M / Series B / Apr 10, 2012 | |
TetraLogic Pharmaceuticals
|
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. ItsNecrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology. | $23M / Series C / Jan 04, 2011 | |
|
TetraLogic Pharmaceuticals
|
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. ItsNecrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology. | $32M / Series C / Aug 10, 2010 | |
PhotoThera
|
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information.Specialtieslaser, medical device, eschemic, stroke,infrared | $50M / Series D / May 22, 2009 | |
OncoMed Pharmaceuticals
|
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cellsâ€. They are leveraging their understanding of these tumor initiating cells to discover and develop noveltherapeutics that could provide important alternatives for the treatment of cancer. | $154M / Series B / Nov 04, 2008 | |
|
Silk Road Medical
|
Silk Road Medical believes that by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with arterial disease. Our history is one of deep collaboration with vascular surgeons and our future will be guided by continuous learning, observation, and improvement.Silk Road advances patient care. Silk Road Medical Inc. was founded in 2007 and is based in Sunnyvale, California. | $3.4M / Series A / May 07, 2007 | |
Bacchus Vascular
|
Bacchus Vascular, Inc. offers medical devices for the treatment of occlusive vascular disease to interventional radiologists and vascular surgeons in the United States. It provides the TRELLIS-8 Peripheral Infusion System, an isolated thrombolysis catheter that enables treatment of deep vein thrombosis and arterial occlusions by targeted deliveryof clot-dissolving drugs. The company was founded in 1999 and is based in Santa Clara, California. | $6.5M / Apr 17, 2007 | |
| See all 12 investments → | |||
Co-Investors
About The Vertical Group
The Vertical Group is a New Jersey-based venture capital firm focused on the fields of medical technology and biotechnology.
The Vertical Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jack W. Lasersohn
General Partner
|
|||
John E. Runnells
General Partner
|
|||
Richard B. Emmitt
Founder/Managing Director
|
|||
Tony Chou
General Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Jack W. Lasersohn invest in?
Jack W. Lasersohn invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series C and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jack W. Lasersohn last invest?
The most recent investment recorded for Jack W. Lasersohn closed in Jul 2017. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
